Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Vertex Pharmaceuticals (NasdaqNM:VRTX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Location
130 Waverly Street
Cambridge, MA 02139
Phone: (617) 577-6000
Fax: (617) 576-2109
Email: partridge@vpharm.com
Employees (last reported count): 455
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Subsidiaries
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 400 MidCap
Ownership
·Insider and 5%+ Owners: 28%
·Institutional: 76% (105% of float)
(380 institutions)
·Net Inst. Buying: 1.21M shares (+2.57%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Vertex Pharmaceuticals Inc. is a biotechnology company that seeks to discover, develop and commercialize novel small molecule drugs that address significant markets with major unmet medical needs, including the treatment of viral diseases, cancer, auto-immune and inflammatory diseases, and neurological disorders. The Company's drug design platform integrates advanced biology, chemistry, biophysics and information technologies to make the drug discovery process more efficient and productive. To date, Vertex has discovered and advanced one product that has reached the market, including the HIV protease inhibitor Agenerase (amprenavir), and the Company has 12 additional drug candidates in development.
More from Market Guide: Expanded Business Description

Financial Summary
Vertex Pharmaceuticals discovers, develops and markets small molecule drugs that address the treatment of viral diseases, cancer, autoimmune and inflammatory diseases, and neurological disorders. For the six months ended 6/30/01, total revenues rose 15% to $40.5 million. Net loss before accounting change rose 62% to $21 million. Results reflect increased amounts earned under collaborative R&D agreements, offset by higher research and development costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Joshua Boger, Ph.D., 49
Chairman, CEO
$678K$5.5M
Vicki Sato, Ph.D., 52
Pres
489K1.3M
John Alam, M.D., 39
Sr. VP, Drug Evaluation and Approval
283K2.1M
Mark Murcko, Ph.D.
VP, CTO and Chair of the Scientific Advisory Board
--  --  
Lynne Brum, 37
VP, Corp. Communications and Market Devel.
206K2.4M
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:VRTXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$25.625
Recent Price$36.89 
52-Week High
on 1-Nov-2000
$99.25 
Beta1.06 
Daily Volume (3-month avg)866.2K
Daily Volume (10-day avg)564.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-57.1%
52-Week Change
relative to S&P500
-42.5%
Share-Related Items
Market Capitalization$2.23B
Shares Outstanding60.5M
Float43.6M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 24-Aug-2000
Per-Share Data
Book Value (mrq)$6.31 
Earnings (ttm)-$0.79 
Earnings (mrq)-$0.20 
Sales (ttm)$1.43 
Cash (mrq)$5.29 
Valuation Ratios
Price/Book (mrq)5.85 
Price/EarningsN/A 
Price/Sales (ttm)25.75 
Income Statements
Sales (ttm)$83.5M
EBITDA (ttm)-$42.6M
Income available to common (ttm)-$44.5M
Profitability
Profit Margin (ttm)-53.3%
Operating Margin (ttm)-63.8%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-6.34%
Return on Equity (ttm)-13.82%
Financial Strength
Current Ratio (mrq)8.51 
Debt/Equity (mrq)0.91 
Total Cash (mrq)$320.0M
Short Interest
As of 8-Aug-2001
Shares Short3.10M
Percent of Float7.1%
Shares Short
(Prior Month)
5.85M
Short Ratio3.46 
Daily Volume895.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.